Study finds NovaTears increases tear film, lipid layer thickness.
06/05/2018
June 5, 2018 – Gerard Garhöfer, MD, and colleagues reported in a randomized study, that NovaTears has the ability to restore the tear film over time, due to the novel mode of action – perfluorohexyloctane – preventing evaporation by stabilizing the lipid layer.
Study finds NovaTears increases tear film, lipid layer thickness
06/04/2018
June 4, 2018 – Gerard Garhöfer, MD, and colleagues reported in a randomized study, that NovaTears has the ability to restore the tear film over time, due to the novel mode of action – perfluorohexyloctane – preventing evaporation by stabilizing the lipid layer.
Study finds NovaTears® can increase tear film thickness
05/07/2018
May 7, 2018 – At ARVO 2018, Gerhard Garhöfer, MD, discusses our clinical NT-004 study investigating the effect of NovaTears® on tear film thickness in dry eye patients:
Novaliq to Present Scientific and Clinical Research During the 2018 Association for Research in Vision and Ophthalmology Meeting in Honolulu, HI
04/24/2018
Heidelberg, Germany – April 24, 2018 – Novaliq GmbH, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, today announced that four scientific posters will be presented at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Meeting in Honolulu, HI (April 29-May 3).
Novaliq seeks entry into US dry eye market – Interview with Bernhard Günther @ASCRS
04/16/2018
April 16, 2018 – During OIS@ASCRS2018 in Washington, D.C., Bernhard Günther gave an interview with Healio/OSN about Novaliq Inc.’s clinical and business progress to date. Mr. Günther shared his views on how Novaliq plans to leverage the benefits of the company‘s water-free EyeSol® drug delivery technology to serve the growing U.S. eye care market.
What opportunities does the dry eye challenge hold for the ophthalmology industry?
03/19/2018
March 19, 2018 –Christian Roesky, PhD, CEO and managing director of Novaliq GmbH, explains how the company’s water-free ophthalmic therapies can bring new treatments to ophthalmology’s most vexing conditions including dry eye. And what valuable lessons has he learned as CEO of the start-up.
Novaliq Announces First Patient Enrolled in Its SEECASE Phase 2 Trial of NOV03 for the Treatment of Dry Eye Disease
01/08/2018
Heidelberg, Germany – January 8, 2018 – Novaliq GmbH, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, today announced that it has begun randomization of patients in its SEECASE Phase 2 clinical trial for the treatment of dry eye disease (DED).
Novaliq Establishes U.S. Subsidiary in Cambridge, Massachusetts to Strengthen Its Presence in the Growing U.S. Eye Care Market
01/08/2018
Heidelberg, Germany – January 8, 2018 – Novaliq GmbH, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, today announced the formation of its new subsidiary, Novaliq Inc., which will be located in Cambridge, Massachusetts, U.S.